Current Pharmaceutical Biotechnology
Title:Meet Our Editorial Board Member
Volume: 20 Issue: 12
Author(s): Massimiliano Filosto
Affiliation:
Export Options
About this article
Cite this article as:
Filosto Massimiliano , Meet Our Editorial Board Member, Current Pharmaceutical Biotechnology 2019; 20 (12) . https://dx.doi.org/10.2174/138920102012190919091841
DOI https://dx.doi.org/10.2174/138920102012190919091841 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
Call for Papers in Thematic Issues
Artificial Intelligence in Bioinformatics
Bioinformatics is an interdisciplinary field that analyzes and explores biological data. This field combines biology and information system. Artificial Intelligence (AI) has attracted great attention as it tries to replicate human intelligence. It has become common technology for analyzing and solving complex data and problems and encompasses sub-fields of machine ...read more
Latest Advancements in Biotherapeutics
The scope of this thematic issue is to comprehensively explore the rapidly evolving landscape of biotherapeutics, emphasizing breakthroughs in precision medicine. Encompassing diverse therapeutic modalities, the issue will delve into the latest developments in monoclonal antibodies, CRISPR/Cas gene editing, CAR-T cell therapies, and innovative drug delivery systems, such as nanoparticle-based ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Biological Markers of Alzheimers Disease and Mild Cognitive Impairment
Current Alzheimer Research Exploring the Role of Monoamine Oxidase Activity in Aging and Alzheimer’s Disease
Current Pharmaceutical Design Targeted Vascular Drug Delivery in Cerebral Cancer
Current Pharmaceutical Design Editorial [Hot Topic: Tocotrienols: Potential Drug Targets for Cardiovascular, Cancer and Neurological Diseases (Executive Guest Editor: Dipak K. Das)]
Current Pharmaceutical Design Chelating Agents for Metal Intoxication
Current Medicinal Chemistry Cannabinoid Receptor Type 2 Activation Yields Delayed Tolerance to Focal Cerebral Ischemia
Current Neurovascular Research Drugs of Abuse in Pregnancy, Poor Neonatal Development, and Future Neurodegeneration. Is Oxidative Stress the Culprit?
Current Pharmaceutical Design Advances of Phenoxazines: Synthesis, Reactivity and Their Medicinal Applications
Current Medicinal Chemistry The Application of Mass Spectrometry to Proteomics and Metabolomics in Biomarker Discovery and Drug Development
Current Molecular Pharmacology Protein Aggregation and Self Assembly in Health and Disease
Current Proteomics The Effects of Curcumin on Astrocytes in Common Neurodegenerative Conditions
Mini-Reviews in Medicinal Chemistry Relevance of Breast Cancer Resistance Protein to Brain Distribution and Central Acting Drugs: A Pharmacokinetic Perspective
Current Drug Metabolism Small Diverse Antioxidant Functionalities for Oxidative Stress Disease Drug Discovery
Mini-Reviews in Medicinal Chemistry Targeting TRPs in Neurodegenerative Disorders
Current Topics in Medicinal Chemistry Interaction of Prolyl Oligopeptidase with α-Synuclein
CNS & Neurological Disorders - Drug Targets Novel Indications for Benzodiazepine Antagonist Flumazenil in GABA Mediated Pathological Conditions of the Central Nervous System
Current Pharmaceutical Design Therapeutic Opportunities for Trophic Factors in Brain Inflammation
Current Pharmaceutical Analysis subject Index To Volume 1
Current Drug Targets - CNS & Neurological Disorders Unfolded Protein Response in Chronic Obstructive Pulmonary Disease: Smoking, Aging and Disease: A SAD Trifecta
Current Molecular Medicine Targeting Cancer and Neuropathy with Histone Deacetylase Inhibitors:Two Birds with One Stone?
Current Cancer Drug Targets